115 E Fort Union Blvd, Midvale, UT 84047
115 E Fort Union Blvd, Midvale, UT 84047
Conditions We Treat
A common, often under-addressed side effect of cancer treatment — and an area of active, promising research.
Chemotherapy-induced peripheral neuropathy (CIPN) is nerve damage caused by certain chemotherapy drugs, particularly platinum-based agents, taxanes, and a few other drug classes. It typically appears in a symmetric pattern — often described as a "stocking and glove" distribution — starting in the feet and hands and sometimes progressing toward the ankles and wrists. Depending on the specific chemotherapy regimen, CIPN affects a significant portion of patients, and for some it persists well beyond the completion of treatment.
If you're dealing with CIPN, there's a good chance you've already been told that treatment options are limited. That's a fair reflection of where conventional pharmacology stands today — but it's also exactly the kind of gap where a multi-mechanism approach like Tetra-Therapy has something meaningful to offer.
CIPN has a different underlying process than diabetic neuropathy. Chemotherapy drugs cause nerve damage through oxidative stress, mitochondrial dysfunction, and inflammation — particularly affecting the sensory nerve cell bodies that sustain long nerve fibers reaching the feet and hands. This is part of why CIPN doesn't always respond the same way diabetic neuropathy does, and why we treat it as its own category rather than assuming one protocol fits every cause of neuropathy.
Your program starts with a complete evaluation, including thermography imaging and a full neurological assessment, so Dr. Campbell has a clear picture of your specific symptom pattern before building your protocol. Two areas of therapy have specific, condition-relevant research behind them for CIPN:
Laser therapy. A randomized, sham-controlled clinical trial of 70 CIPN patients found that photobiomodulation (the mechanism behind our Class IV laser therapy) produced significant improvement in the large majority of patients, with benefits beginning within weeks. See the research →
Ozone therapy. A 2023 review of ozone therapy for CIPN cites a small preliminary study showing meaningful pain reduction, with a larger controlled trial currently underway. Our protocol uses meridian point injections rather than the rectal insufflation method studied, so we consider this a promising but still-developing area of evidence. See the research →
As with every patient, your full program addresses all four Tetra-Therapy goals — not just these two — calibrated to your specific presentation and how your thermography evolves over the course of treatment.
If you're currently in active cancer treatment or recently completed it, your oncology team remains central to your care. We coordinate around your treatment timeline and encourage open communication between our office and your oncologist, particularly if you're still receiving chemotherapy. This program is not a substitute for oncologic care, and any decision about your cancer treatment plan should be made with your oncology team.
I'm still receiving chemotherapy. Can I start this program now?
This is a conversation to have directly with Dr. Campbell and your oncology team at your evaluation. Timing depends on your specific treatment plan and current health status.
My chemotherapy ended over a year ago and the neuropathy hasn't gone away. Is it too late to do anything?
CIPN can persist well beyond the end of treatment, and that doesn't mean nothing more can be done. A complete evaluation is the best way to understand your specific situation and what a reasonable path forward looks like.
Will this program interfere with my cancer treatment?
Our protocol does not involve chemotherapy drugs or medications that would interact with your treatment. We coordinate with your oncology team and encourage transparency about your full treatment picture at your evaluation.
Is this treatment specific to a particular type of cancer or chemotherapy drug?
No — CIPN can result from several different chemotherapy classes, and our evaluation is designed to assess your specific symptom pattern regardless of which treatment caused it.
A complete evaluation, including thermography imaging, is $49. No pressure, no obligation.
Book Your EvaluationIndividual results vary. This page describes general information about chemotherapy-induced peripheral neuropathy and the Neuro-Restore™ Program's general approach to it, and is not medical advice or a guarantee of outcome. This program does not treat cancer and is not a substitute for oncologic care. See our Medical Disclaimer for more information.